This presentation details the development, understanding, and scale-up of an aseptic crystallization, which utilizes a novel wet milling during anti-solvent addition approach, that consistently delivers desired physical properties that result in an acceptable uniformity of the final drug product formulation.
The drug substance described is formulated as a sterile powder blend in a vial in combination with other sterile powder drug substances, and needs to fit into the existing formulation process and equipment. The use of an aseptic blending operation requires that the final crystallization of the drug substance be performed in an aseptic environment as well. Due to the nature of the sterile processing environment, sampling of the powder blend during processing to verify blend uniformity is not possible, and sampling of the crystal slurry during processing to ensure suitable physical properties is not feasible, so process adjustments based on in-process testing cannot be done.
Chemical Engineering Research and Development group (CERD) | Merck
Dan Minkler earned a BS in Chemical Engineering from North Carolina State University. Dan worked for a year at Engineered Biopharmaceuticals doing process development on a novel spray drying application. He then took a position at Biogen working primarily on perfusion cell culture applications. Currently, Dan is in the Chemical Engineering Research and Development group (CERD) at Merck, Inc. focusing on the development and validation of an aseptic crystallization.